Last updated: July 28, 2026
Kefzol is the brand name of cefazolin (a first-generation cephalosporin) marketed for multiple bacterial infection indications. No patent-driven exclusivity or branded clinical-trials pipeline updates materially impact market access in the near term because cefazolin is long off-patent in major markets and is widely available as approved generics. Market dynamics therefore track hospital formulary behavior, group purchasing organization pricing, and antimicrobial stewardship constraints rather than new proprietary clinical development.
What is Kefzol (cefazolin) and how is it used in hospitals?
Kefzol is cefazolin for injection. It is used to treat susceptible bacterial infections and is a standard perioperative prophylaxis antibiotic in surgery settings where first-generation cephalosporin coverage is appropriate.
What indications drive cefazolin use?
Common hospital use cases include:
- Surgical site infection prophylaxis (perioperative prophylaxis)
- Skin and soft tissue infections
- Bone and joint infections where susceptible organisms are expected
- Certain urinary tract infections
- Other susceptible Gram-positive bacterial infections
How do formulary and stewardship decisions shape demand?
Hospital procurement shifts cefazolin volume primarily through:
- Standard perioperative prophylaxis protocols by surgical specialty
- Local antibiogram-driven susceptibility patterns
- Infection control and stewardship guidance that favors narrow-spectrum agents when appropriate
- Supply continuity and price competitiveness among multisource generics
Practical demand driver: Cefazolin’s core role is procedural prophylaxis plus routine susceptible bacterial infections in inpatient settings. Those settings typically prioritize low-cost, reliable supply.
What is the latest Kefzol (cefazolin) clinical trials update?
There is no ongoing branded “Kefzol” late-stage development program that would support an investor-grade pipeline update. Cefazolin is an established off-patent antimicrobial with generic manufacturing and routine clinical use. Clinical activity in cefazolin has historically shifted to:
- Comparative effectiveness studies
- Pharmacokinetic and dosing optimization studies
- Resistance and stewardship evaluations
- Trials involving cefazolin prophylaxis regimens rather than new proprietary mechanisms
What kinds of cefazolin clinical studies are most common?
Recent and ongoing research patterns in cefazolin tend to fall into:
- Perioperative dosing and timing optimization
- Alternative routes or preparation comparisons (where regulators and guidelines allow)
- Penetration or PK in special populations (obesity, renal impairment, pediatrics)
- Surgical prophylaxis strategy comparisons across procedures
Does Kefzol have a current Phase 3 catalyst?
For business planning, the practical answer is no: market access is not contingent on a new Phase 3 outcome, because cefazolin’s active ingredient is widely genericized.
What is the Orange Book status of Kefzol (cefazolin) and how many approved products exist?
Kefzol is cefazolin sodium for injection. In the U.S., cefazolin is widely available as abbreviated new drug applications (ANDAs) for generic versions of cefazolin injections. Branded exclusivity is not a meaningful gating factor for competitive entry.
What does this mean for “Kefzol” market protection?
- Any “Kefzol” brand manufacturing rights do not translate into new intellectual property barriers at the active ingredient level.
- Generic competition is already entrenched through multiple approved label products.
When does Kefzol (cefazolin) lose exclusivity and what patents protect cefazolin?
Cefazolin’s original composition-of-matter and early formulation protection is long expired in major jurisdictions. Current market constraints do not typically hinge on patent expiry for cefazolin.
What patent estate exists today?
For cefazolin, the binding constraints are usually:
- Process or formulation patents held by individual manufacturers for specific product presentations (if any still in force)
- Secondary patents that can be fragmented by presentation, container configuration, or manufacturing process
In practice, these do not function like a single unified “brand protection” timeline because:
- The active ingredient is widely manufactured.
- Multiple ANDA sponsors compete in parallel.
Which companies manufacture and sell cefazolin injections that compete with Kefzol?
The competitive set is the generic cefazolin injection market rather than a single brand-to-brand comparison. In practice, buyers switch among:
- Multisource generic injectables companies
- Sterile injectables specialists
- Authorized generic programs when available
Commercially relevant point: Cefazolin is a commodity-like injectable with buyer preference for consistent supply at the lowest acceptable price.
What clinical and safety endpoints matter for cefazolin versus other perioperative antibiotics?
Even without branded clinical pipeline catalysts, procurement decisions depend on performance across endpoints used in stewardship and guideline compliance.
Common clinical endpoints in perioperative cefazolin comparisons
- Surgical site infection rates (SSI)
- Timing of prophylaxis relative to incision
- Infection severity and microbiology (Gram-positive coverage focus)
- Adverse events: hypersensitivity, renal tolerance, infusion reactions
How do clinicians weigh cefazolin against alternatives?
Hospitals compare against:
- Other beta-lactams used in prophylaxis
- Vancomycin or clindamycin in MRSA-directed regimens
- Broader-spectrum agents when Gram-negative coverage is needed
Cefazolin typically wins on:
- Narrow-spectrum fit
- Cost and supply reliability
- Familiar administration and dosing protocols
Market analysis: How big is the cefazolin injection market and what drives volume?
Cefazolin volume is tied to inpatient surgical procedures and inpatient treatment of susceptible infections, not to outpatient chronic use.
Key demand drivers
- U.S. and EU surgical procedure volumes
- Perioperative protocol adherence
- Increasing focus on antimicrobial stewardship and narrowing where appropriate
- Reimbursement dynamics and hospital budgeting cycles
- Supply shocks and manufacturing constraints that can briefly shift buyers
Key supply and pricing drivers
- Multisource manufacturing capacity
- Sterile injectables plant utilization and quality system capacity
- Group purchasing organization (GPO) contract cycles
- Hospital tender processes and rebid outcomes
Core market structure: Cefazolin injections behave like a price-competitive sterile generic commodity.
What pricing and margin trends should be assumed for Kefzol-like cefazolin injections?
Because the drug is genericized, pricing is driven by:
- Competitive bidding and contract concessions
- Periodic price volatility during manufacturing disruptions
- Volume commitments tied to formulary inclusion
Typical market behavior in commodity sterile generics
- Baseline pricing remains low relative to novel therapeutics
- Short-term spikes occur when supply tightens
- Long-term downward pressure persists as additional ANDA competitors maintain capacity
What is the 3- to 5-year market projection for Kefzol (cefazolin)?
Projection basis: In an off-patent, multisource injectable, the base case is stable-to-moderate growth tied to procedure volumes, with pricing pressure offset by demand stability.
Base case (most likely)
- Revenue growth tracks incremental volume growth from surgical procedure volumes and inpatient admissions.
- Average realized prices remain under margin pressure due to competitive tendering.
Bull case
- Prolonged supply constraints among fewer competitors or manufacturing issues at other suppliers can temporarily improve realized pricing for surviving suppliers.
- Expanded protocol adoption in additional surgical specialties.
Bear case
- Intensified price competition via renewed GPO bids and additional entrants.
- Supply normalization across the market compresses prices.
- Updated stewardship guidance reduces use in certain procedures.
What generic entry risks exist for Kefzol?
There is no meaningful “new entry risk” for cefazolin at the active ingredient level because:
- ANDA competition already exists.
- Buyers source from multiple suppliers.
- Regulatory clearance has already occurred for multiple cefazolin injection presentations.
The practical risks for a specific brand SKU (“Kefzol” presentation) relate to:
- Contract losses at the hospital level
- Temporary supply issues for that labelholder
- Product discontinuations or packaging changes that can force substitution
How does Kefzol compare with other perioperative antibiotics in market and clinical positioning?
Cefazolin vs broader-spectrum beta-lactams
- Cefazolin typically has a narrow-spectrum positioning aligned to stewardship.
- Broader agents compete primarily when infection risk profiles justify expanded coverage.
Cefazolin vs vancomycin-based prophylaxis
- Cefazolin is typically first-line in MSSA and MSSA-matched settings.
- Vancomycin is used in MRSA-directed prophylaxis protocols.
Net effect: Cefazolin is often the default unless local resistance patterns or procedure risk profiles require alternatives.
What regulatory actions and FDA manufacturing risks can affect supply of Kefzol-like products?
Market availability for cefazolin injections can change rapidly from:
- Sterility assurance failures or remediation plans
- Batch recalls or distribution holds
- FDA warning letters tied to sterile manufacturing controls
- Recalls driven by particulate/sterility concerns
Because cefazolin is commodity-like, supply interruptions can translate into short-term pricing improvements for remaining suppliers.
What litigation or Paragraph IV challenges affect Kefzol (cefazolin)?
No Paragraph IV litigation is typically a gating issue for cefazolin at this stage because:
- Active ingredient exclusivity is not the competitive bottleneck.
- Multiple approved ANDAs already exist.
- The market is not driven by ongoing brand protection events.
Key takeaways
- Kefzol is cefazolin injection, a long-established off-patent antimicrobial; the market is multisource and commodity-like.
- Clinical-trials “updates” in cefazolin are not proprietary late-stage catalysts; most activity is optimization or comparative effectiveness tied to perioperative protocols and stewardship.
- Market demand tracks inpatient procedures and susceptibility patterns more than brand-specific innovation.
- Over the next 3 to 5 years, expect revenue to track volume modestly while pricing remains pressured by competitive tendering, with periodic volatility tied to sterile supply constraints.
- Patent-driven exclusivity timelines are not a meaningful business planning lever for Kefzol; supply continuity, formulary placement, and GPO contract cycles dominate.
FAQs
1) Is Kefzol still available in the U.S. market as cefazolin injection?
Yes. Cefazolin injections remain available through branded and generic labelholders, with extensive multisource availability.
2) What perioperative dosing timing affects cefazolin efficacy?
Efficacy is linked to timing relative to incision and adequate tissue exposure; dosing protocols vary by surgery and patient factors such as weight and renal function.
3) Does cefazolin have MRSA coverage, and how does that affect usage?
Cefazolin is not reliable MRSA-directed prophylaxis in typical protocols; MRSA prevalence drives selection of alternatives in specified settings.
4) What are the main reasons hospitals switch cefazolin suppliers?
GPO rebid economics, contract award terms, and supply reliability (manufacturing continuity and quality history).
5) Are there any meaningful new patent barriers for cefazolin injection entrants?
At the active ingredient level, no; competition is already established across ANDA products. Remaining barriers, if any, are presentation- or process-specific and do not function like primary brand exclusivity.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- U.S. Food and Drug Administration. Drug Shortages (archived/current supply notifications). https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
